abstract |
The present invention relates to the use of an EP4 receptor ligand in the manufacture of a medicament for the treatment of IL-6 involved diseases. Also relates to the assay comprising: culturing peripheral whole blood with a test compound; and determining the effect of the compound on PGE2-induced whole blood cells activation. |